Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.64 |
| ▸ | FADS1 | O60427 | 2/20 | 0.64 |
| ▸ | LCK | P06239 | 2/20 | 0.63 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.58 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | PRNP | P04156 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 3/20 | 0.56 |
| ▸ | ABL2 | P42684 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5568069 | 0.86 | JAK2 (0.56) | EGFRFADS1LCKTTBK1TTBK2 | |
| SCHEMBL9017044 | 0.86 | EGFR (0.68) | EGFRFADS1LCKTTBK1TTBK2 | |
| SCHEMBL5564578 | 0.85 | MAPT (0.55) | EGFRFADS1LCKERBB2MAPT | |
| SCHEMBL5565322 | 0.85 | AURKA (0.52) | EGFRFADS1LCKERBB2MAPT | |
| Hydrochloric Acid SCHEMBL11091908 | 0.84 | EGFR (0.68) | EGFRFADS1LCKTTBK1TTBK2 | |
| SCHEMBL5569470 | 0.84 | EGFR (0.58) | EGFRTTBK1TTBK2ERBB2KDM4E | |
| SCHEMBL4787336 | 0.83 | EGFR (0.64) | EGFRFADS1LCKTTBK1TTBK2 | |
| SCHEMBL5569425 | 0.83 | EGFR (0.72) | EGFRERBB2MAPK1FBP1 | |
| SCHEMBL5569119 | 0.82 | TP53 (0.50) | EGFRFADS1LCKMAPTTP53 | |
| SCHEMBL17532922 | 0.81 | EGFR (0.72) | EGFRFADS1LCKERBB2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | claimed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | IRF3, PML, TPMT | EGFR 1445/4885FADS1 4484/4885LCK 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.